Johnson & JohnsonvsOrthoPediatrics

JNJ and KIDS stock compared: price, dividend, valuation and results, from SEC filings.

KIDS

OrthoPediatrics Corp.

$31.74

Value $802M

-2.37%
KIDS's page

Johnson & Johnson (JNJ) has a market value of $652B and OrthoPediatrics (KIDS) $802M. Over the last year, with dividends, JNJ moved +36.6% and KIDS +91.0%. Dividend yield: JNJ 1.95%, KIDS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    KIDS$802M

    JNJ is 812 times KIDS

  • Revenue, 12 months

    JNJ$99.3B

    KIDS$264M

    JNJ is 376 times KIDS

  • Net income, 12 months

    JNJ$16.1B

    KIDS-$34M

  • Operating margin

    JNJ–

    KIDS-9.4%

  • ROIC

    JNJ12.4%

    KIDS-4.4%

    16.8 points apart

  • P/E

    JNJ40.5

    KIDS–

  • Dividend yield

    JNJ2.0%

    KIDS0.0%

    2.0 points apart

  • 5-year return

    JNJ+90.9%

    KIDS-48.2%

    139.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+90.9%

KIDS-48.2%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsKIDSWith dividends
1 year since November 19, 2025+36.6%Price +33.6%+91.0%Price +91.0%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%-0.3%-0.1% a yearPrice -0.3%
5 years since November 19, 2021+90.9%+13.8% a yearPrice +66.0%-48.2%-12.3% a yearPrice -48.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonKIDSOrthoPediatrics

Valuation

JNJKIDS
Valuation
Price$270.47$31.74
Market value$652B$802M
Enterprise value (EV)$679B$859M
P/E40.5–
P/E, 5-year median21.9–
P/B8.02.4
EV/EBIT38.3–
Free cash flow yield3.2%0.4%

Results and growth

JNJKIDS
Results and growth
Revenue, 12 months$99.3B$264M
Net income, 12 months$16.1B-$34M
Free cash flow, 12 months$20.6B$3.2M
Earnings per share, 12 months$6.59-$1.43
Revenue growth, year on year6.1%15.5%
Revenue growth a year, past+2.7%over 5 years+27.2%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJKIDS
Margins and returns on capital
Gross margin67.6%73.8%
Operating margin–-9.4%
Net margin16.2%-12.8%
ROIC12.4%-4.4%
ROE19.7%-9.9%

Balance sheet

JNJKIDS
Balance sheet
Cash$17.2B$44M
Total debt$44.7B$101M
Net debt / EBITDA1.1–
Interest cover18.0×-9.4×

Dividends and buybacks

JNJKIDS
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or KIDS

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or OrthoPediatrics?

By market value, Johnson & Johnson ($652B) is about 812.4 times OrthoPediatrics ($802M), at today's prices.

How did JNJ and KIDS stock do over the last 5 years?

Since November 19, 2021, JNJ's price moved +66.0% and KIDS's -48.2%. With dividends: JNJ +90.9% (+13.8% a year), KIDS -48.2% (-12.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or KIDS?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for OrthoPediatrics. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or OrthoPediatrics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -12.8% for OrthoPediatrics, and the operating margin – and -9.4%. Revenue was $99.3B and $264M.

Which is the better investment, Johnson & Johnson or OrthoPediatrics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.